LIM-domain-only 4 (LMO4) enhances CD8+ T-cell stemness and tumor rejection by boosting IL-21-STAT3 signaling

Roland Christian Schelker(University Hospital Regensburg), Luca Gattinoni(National Cancer Institute)
Signal Transduction and Targeted Therapy
August 9, 2024
Cited by 17


Related Papers